Hospitalized lung transplant recipients face high rates of respiratory failure, lung function decline, and increased mortality risk.
RT’s Three Key Takeaways:
- High Risk of Respiratory Failure: More than half of adult lung transplant recipients hospitalized with respiratory syncytial virus developed hypoxic respiratory failure, and nearly one in five required mechanical ventilation.
- Ventilation Tied to Higher Mortality: Older age increased the odds of needing invasive mechanical ventilation, an intervention that was strongly associated with secondary infections and 90-day mortality.
- Lasting Loss of Pulmonary Function: Nearly half of evaluated patients suffered a decline in lung function exceeding 10%, while acute graft rejection occurred in more than 12% of cases following infection.
Hospitalized adult lung transplant recipients who contract respiratory syncytial virus (RSV) experience substantial rates of respiratory failure, sustained decreases in graft function, and increased mortality, according to multicenter study findings published in Open Forum Infectious Diseases.
The international study evaluated 155 adult lung transplant recipients hospitalized with laboratory-confirmed RSV between 2016 and 2019 across seven transplant centers located in the US, Canada, and Australia. The median patient age was 61 years, and RSV infection occurred at a median of 14 months following transplantation, according to the researchers.
Elevated Odds of Respiratory Failure
The study demonstrated that RSV infection frequently leads to acute pulmonary deterioration in immunocompromised recipients. Investigators reported that hypoxic respiratory failure occurred in 58.7% of hospitalized patients, 17.4% required mechanical ventilation, and all-cause mortality within 90 days reached 7.7%.
Specific baseline characteristics and clinical presentations were tied to worsening respiratory status. Patients who required supplemental oxygen before developing the viral infection had significantly elevated odds of developing hypoxic respiratory failure (odds ratio [OR]: 4.81), according to study data. In addition, the presence of lower respiratory tract symptoms, including cough, chest pain, and shortness of breath, was associated with higher odds of hypoxic respiratory failure (OR: 3.74).
Mechanical Ventilation and Secondary Infections
Older age was identified as an important clinical risk factor, with each additional year of age increasing the odds of requiring mechanical ventilation (OR: 1.06 per year), according to the investigators.
When examining medical therapies, oral ribavirin was associated with lower odds of mechanical ventilation (OR: 0.34). However, the study noted that this association lost statistical significance when oral and inhaled formulations were combined in the analysis, and oral ribavirin did not demonstrate an improvement in 90-day survival. The researchers emphasized that observational data cannot prove efficacy because treatment choices often reflect baseline differences in patient illness severity.
Hospitalized recipients also experienced high rates of superinfections. Secondary bacterial or fungal infections developed in 33.5% of patients within 90 days of RSV diagnosis, and mechanical ventilation was associated with nearly fourfold greater odds of secondary infection (OR: 3.71), according to the study.
Long-Term Graft Impact and Clinical Vigilance
RSV also caused measurable declines in respiratory mechanics and graft health. Among 61 patients with available paired pulmonary function tests, median forced expiratory volume in one second (FEV1) fell from 2.01 liters before infection to 1.69 liters afterward. The researchers found that nearly half of these patients experienced FEV1 reductions exceeding 10%, and allograft rejection occurred in 12.3% of the cohort following infection.
The study authors highlighted the critical role of respiratory support management, observing that mechanical ventilation was strongly associated with 90-day mortality (hazard ratio: 7.79).
While the authors noted limitations, including the retrospective study design, a limited overall number of deaths, the inclusion of only hospitalized patients, and data that predated modern RSV vaccination options, they concluded that the findings reinforce the need for close respiratory monitoring, rapid recognition of secondary infections, and targeted preventive strategies across transplant healthcare settings.
Reference
Mendoza MA et al. Risk factors for hypoxia, mechanical ventilation, and mortality in lung transplant recipients hospitalized with respiratory syncytial virus: A multicenter international cohort study. Open Forum Infect Dis. 2026;doi:10.1093/ofid/ofag623.
This article was originally published by AMJ and was made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
